Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD OncLive PodcastIn today's episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 31, 2026) OncLive Podcast In today’s episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Blackstone closes $6.3B fund for life sciences investingNext: AZ considers filings for long-acting Strensiq follow-up Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
